# Transcutaneous Auricular Vagus Nerve Stimulation for Treating Emotional Dysregulation and Inflammation in Common Neuropsychiatric Disorders

**Authors:** William J. Tyler

PMC · DOI: 10.3390/brainsci16010008 · Brain Sciences · 2025-12-20

## TL;DR

This paper explores how transcutaneous auricular vagus nerve stimulation (taVNS) can help treat mental health issues by targeting both brain and immune system dysfunction.

## Contribution

The paper introduces taVNS as a novel non-invasive method to address emotional and inflammatory dysregulation in neuropsychiatric disorders.

## Key findings

- taVNS modulates the noradrenergic system to improve mood and stress responses.
- taVNS suppresses pro-inflammatory cytokines via the cholinergic anti-inflammatory pathway.
- taVNS shows potential to restore psychoneuroimmunological balance in mental health conditions.

## Abstract

Development of new therapeutic approaches and strategies for common neuropsychiatric disorders, including Major Depressive Disorder, anxiety disorders, and Post-Traumatic Stress Disorder, represent a significant global health challenge. Recent research indicates that emotional dysregulation and persistent inflammation are closely linked and serve as key pathophysiological features of these conditions. Emotional dysregulation is mechanistically coupled to locus coeruleus and norepinephrine (LC-NE) or noradrenergic system activity. Stemming from chronic stress, persistently elevated activity of the LC-NE system leads to hypervigilance, anxious states, and depressed mood. Concurrently, these symptoms are marked by systemic inflammation as indicated by elevated pro-inflammatory cytokines, and central neuroinflammation indicated by microglial activation in brain regions and networks involved in mood regulation and emotional control. In turn, chronic inflammation increases sympathetic tone and LC-NE activity resulting in a vortex of psychoneuroimmunological dysfunction that worsens mental health. Transcutaneous auricular vagus nerve stimulation (taVNS) in a non-invasive neuromodulation method uniquely positioned to address both noradrenergic dysfunction and chronic inflammation in neuropsychiatric applications. Evidence spanning the past decade demonstrates taVNS works via two complementary mechanisms. An ascending pathway engages vagal afferents projecting to the LC-NE system in the brain stem, which has been shown to modulate cortical arousal, cognitive function, mood, and stress responses. Through descending circuits, taVNS also modulates the cholinergic anti-inflammatory pathway to suppress the production of pro-inflammatory cytokines like TNF-α and IL-6 mitigating poor health outcomes caused by inflammation. By enhancing both central brain function and peripheral immune responses, taVNS has shown significant potential for recalibrating perturbed affective-cognitive processing. The present article describes and discusses recent evidence suggesting that taVNS offers a promising network-based paradigm for restoring psychoneuroimmunological homeostasis in common neuropsychiatric conditions.

## Linked entities

- **Chemicals:** IL-6 (PubChem CID 165368475)
- **Diseases:** Major Depressive Disorder (MONDO:0002009), Post-Traumatic Stress Disorder (MONDO:0005146)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** depressed mood (MESH:D003866), emotional (MESH:D003072), anxiety disorders (MESH:D001008), Emotional Dysregulation (MESH:D021081), anxious states (MESH:D018458), noradrenergic dysfunction (MESH:D006331), Inflammation (MESH:D007249), neuroinflammation (MESH:D000090862), Neuropsychiatric Disorders (MESH:D001523), Post-Traumatic Stress Disorder (MESH:D013313), Major Depressive Disorder (MESH:D003865)
- **Chemicals:** NE (MESH:D009356), norepinephrine (MESH:D009638)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12838753/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12838753/full.md

## References

192 references — full list in the complete paper: https://tomesphere.com/paper/PMC12838753/full.md

---
Source: https://tomesphere.com/paper/PMC12838753